R&D-Innovation > Selected R&D projects > Innovative tools & instrumentation

Innovative tools & instrumentation

  • Valostem - Development of new cell-based in vitro models for ADME/Toxicity screening, based on human adult progenitor/stem cells.

    Characterisation of a new drug candidate during preclinical evaluation includes, in addition to potency and safety an assessment of drug metabolism and pharmacokinetics. Drug metabolism studies require identification of the metabolic pathways of new drug candidate as well as potential drug-drug interaction or drug-induced cell toxicity. These information are essential to the pharmaceutical industry in their decision to bring a lead compound in clinical phase development. However, a large proportion (40%) of drug candidates fail during clinical development due to inadequate ADME/Tox evaluation. Thus, there is a strong need for new, innovative and predictive in vitro cell-based assays for preclinical development of new chemical entities (NCE). This project is therefore designed to develop such a model based on the use of hepatocyte-derived progenitor and stem cells. This project aims at providing a new in vitro model for pharmaco-toxicological studies based on liver-derived mesenchymal progenitor cells and at building on that accumulated knowledge and further develop a model of second generation as efficient but with no issue of original source.

  • Radiotarget - New 188Re-radiolabelled monoclonal antibodies in the fight against liver metastases.

    Early diagnosis of primary cancer, prior to any extension beyond the organ in which it was originally developed, usually allows treatment with surgical resection. However, significant proportions of patients with colorectal, breast or ovary cancers develop spread to the liver (liver metastases). Of these metastatic deposits, almost all are unresecable and cure is not possible. Eradication of such liver metastases might only be accomplished by systemic treatment which can reach cancer cells in all their implantation sites. In order to reduce adverse effects on healthy tissues, such treatment must however selectively target cell tumours. The aim of this project is to obtain a radioimmunotherapy agent, comprising the beta emitter 188Re and a monoclonal antibody able to selectively target and bind in vivo, on specific accessible biomarkers of metastatic liver. The availability of a high specific activity 188Re solution from a generator, with sufficient purity for labelling applications, has to be developed at GMP grade to support the clinical trials. Watch video.

  • Gage - Gallium-68 Automated Generator and Equipments.

    In positron emission tomography (PET), 18F-fluorine was and is still widely used because of both its favorable chemical and radiophysical properties. Nevertheless, it necessitates the proximity of a cyclotron due to its 110 minutes half life. Gallium-68, with its 68 minutes half life, has the dual advantage to be independent of daily delivery, because it is issued from a generator. Moreover, it allows higher resolution imaging than “classical” single photon emission computed tomography (SPECT, using 99-technecium or other radioisotopes). Nowadays, the available generators are using old technologies. Moreover, none of these generators is complying with the current good manufacturing practice (cGMP). The synthesis equipments currently on the market are complex, flexible but uneasy to use, because initially designed for research centers, and mostly not adapted to clinical use. The goal of GAGE project is to make available a set of integrated equipment dedicated to the synthesis of molecules labeled with Gallium-68, adapted to clinical daily use and complying with the cGMP.

  • BioLine - BioLine Holographic Analyses Device.

    The objective of the BioLine project is to further validate and optimize Ovizio’s technology for cell culture monitoring allowing it to analyze in a non invasive and reliable way, key cell culture parameters like cell numbers, cell morphology, viability, distribution of cell sizes and the presence of cell clusters and their sizes. In a second phase the technology will be adapted to allow for real time monitoring of cell cultures in industrial applications. The project will develop two instrumentations based on Ovizio’s existing technology: an “off-line” desktop version (oLine), adapted to the analysis of cell cultures in culture dishes; an “in-line” version (iLine), adapted to real-time monitoring of cell cultures in bioreactors. The project will benchmark and validate the technology in comparison with other classical methods and processes.
  • Neuroatt - Development of a neuronal technology for the detection and the treatment of Attention-Deficit/Hyperactivity Disorder(ADHD).

    NeuroAtt aims at designing novel electrophysiological diagnostic tools (EDT) and brain wave trainers (BWT) in attention deficit hyperactivity disorder (ADHD). It includes the development of analysis methods of multi-channel EEG recordings during sensorimotor and cognitive tasks specifically designed for children. When properly validated, this EDT-BWT will help existing clinical approaches to detect the occurrence of rhythmical brain abnormalities at an early stage. It will also develop viable alternatives as countermeasures for ADHD issues and will provide an efficient BWT based on recent brain computer interaction (BCI) technologies. 
  • AVATAR² - Aortic VAlve TransApically Resected and Replaced

    The AVATAR² project aims to develop a new medical device that will allow to resect the native valve and to place a new one. This new medical device will permit to these new techniques to reach the performances of the open heart surgery with a reduction of the per- and post-operative traumatisms.